Can we afford it?: Ethical consideration of expensive drug treatment for neonates and infants

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 587-589

  Shaul, R Zlotnik ^a   Vitale, D ^b  

^a at the University of Toronto Wagner is also a faculty member of the Canadian Medical Associations' Physician Management Institute   (Canada)

^b Court of Appeal for Ontario ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COURT; DRUG COST; DRUG INDUSTRY; HEALTH CARE AVAILABILITY; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HUMAN; MEDICAL ETHICS; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SOCIAL PSYCHOLOGY;

CANADA; COST-BENEFIT ANALYSIS; DRUG COSTS; GOVERNMENT REGULATION; HEALTH CARE RATIONING; HEALTH POLICY; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PATIENT RIGHTS; PATIENT SELECTION; PREJUDICE; SOCIAL VALUES; TREATMENT OUTCOME;

EID: 70450243002     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.211     Document Type: Short Survey

References (3)

1. Meadwow, W. & Lantos, J. Moral reflections on neonatal intensive care. Pediatrics 123, 595-597 (2009).
2. Poley, M.J. et al. Cost-effectiveness of neonatal surgery: first greeted with skepticism, now increasingly accepted. Pediatr. Surg. Int. 24, 119-127 (2007).
3. Lantos, J.D. Hooked on neonatology: a pediatrician wonders about NICUs' hidden cost of success. Health Affairs 20, 233-240 (2001). R. v. Oakes, 1 S.C.R. 103 (1986).